In the last decade there has been huge progress in identifying molecular mechanisms of lung cancer that can be targeted with specific treatments. In parallel technology advances in genomics, tissue and liquid biopsy have been revolutionary and point to a future where patients may be diagnosed, treated and monitored using precise molecular information detectable in blood samples.

This book presents a timely and comprehensive insight into emerging knowledge that is highly relevant to clinicians and researchers in the field of lung cancer translational research. The book is divided into themes of cancer biology, screening and prevention, liquid biopsy, targeted therapy, chemotherapy, immunotherapy and radiotherapy. It provides up to date evidence for the progress made in these areas as well as unanswered questions and research that remains to be done in order to improve outcomes for patients.

Fiona Blackhall
Institute of Cancer Sciences,
Manchester University and The Christie NHS Foundation Trust,
Manchester, UK